NEW YORK (GenomeWeb News) – Exact Sciences today announced it has expanded its collaboration with Mayo Clinic to include all gastrointestinal cancers and diseases, as well as new cancer screening applications of stool- and blood-based testing.

Exact will still have exclusive rights to commercialize products resulting from the new deal, which builds on a 2009 agreement between it and Mayo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.